FBI

Fortress Biotech

Stock
Stock
Ticker: FBIO
FBIO

Price

Price

CHART BY

Frequently asked questions

The market capitalization of Fortress Biotech is $87.71M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
The Price-to-Earnings (P/E) ratio (TTM) for Fortress Biotech is 0.99. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
Fortress Biotech's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $2.657. EPS indicates the company's profitability on a per-share basis.
Currently, 1 analysts cover Fortress Biotech's stock, with a consensus target price of $5.00. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Fortress Biotech reported a revenue of $68.47M.
Fortress Biotech's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$22.83M. EBITDA measures the company's overall financial performance.
Fortress Biotech has a free cash flow of $120.28M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Fortress Biotech employs approximately 78 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
The free float of Fortress Biotech is 23.05M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$87.71M
EPS (TTM) 
$2.657
Free Float 
23.05M
P/E ratio (TTM) 
0.99
Revenue (TTM) 
$68.47M
EBITDA (TTM) 
-$22.83M
Free Cashflow (TTM) 
$120.28M

Pricing

52W span
$2.185$4.53

Analyst Ratings

The price target is $5.00 and the stock is covered by 1 analysts.

Buy

1

Hold

0

Sell

0

Information

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Employees
78
Industries
Major Pharmaceuticals
Sector
Health Care

Identifier

Primary Ticker
FBIO
Fundamentals & EOD data from FactSet
Join the conversation